Dae Ro Choi

715 total citations
43 papers, 468 citations indexed

About

Dae Ro Choi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Dae Ro Choi has authored 43 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Dae Ro Choi's work include Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Dae Ro Choi is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Dae Ro Choi collaborates with scholars based in South Korea, United States and Nigeria. Dae Ro Choi's co-authors include Jung Han Kim, Hyeong Su Kim, Boram Han, Jung Hye Kwon, Dae Young Zang, Dok Hyun Yoon, Cheolwon Suh, Joo Young Jung, Bum Jun Kim and Baek‐Yeol Ryoo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Cellular Physiology.

In The Last Decade

Dae Ro Choi

43 papers receiving 467 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dae Ro Choi South Korea	14	167	157	98	94	85	43	468
Berna Bozkurt Duman Türkiye	14	195 1.2×	83 0.5×	96 1.0×	64 0.7×	70 0.8×	57	450
Prashanth Giridhar India	11	191 1.1×	137 0.9×	111 1.1×	37 0.4×	96 1.1×	43	507
Ömer Görgün Türkiye	15	131 0.8×	236 1.5×	65 0.7×	65 0.7×	112 1.3×	38	518
Konstantin Schlick Austria	15	255 1.5×	83 0.5×	106 1.1×	133 1.4×	56 0.7×	35	526
Bhuvana A. Setty United States	12	113 0.7×	122 0.8×	133 1.4×	44 0.5×	82 1.0×	45	492
Linda Hershon Canada	12	127 0.8×	146 0.9×	122 1.2×	40 0.4×	166 2.0×	15	437
Pedro Pérez Segura Spain	13	211 1.3×	209 1.3×	67 0.7×	67 0.7×	52 0.6×	56	505
T. Girinsky France	12	250 1.5×	90 0.6×	100 1.0×	128 1.4×	99 1.2×	22	574
H Weinstein United States	13	199 1.2×	235 1.5×	158 1.6×	290 3.1×	70 0.8×	24	720
Luciano Wannesson Switzerland	14	235 1.4×	174 1.1×	112 1.1×	101 1.1×	36 0.4×	31	440

Countries citing papers authored by Dae Ro Choi

Since Specialization

Citations

This map shows the geographic impact of Dae Ro Choi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dae Ro Choi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dae Ro Choi more than expected).

Fields of papers citing papers by Dae Ro Choi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dae Ro Choi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dae Ro Choi. The network helps show where Dae Ro Choi may publish in the future.

Co-authorship network of co-authors of Dae Ro Choi

This figure shows the co-authorship network connecting the top 25 collaborators of Dae Ro Choi. A scholar is included among the top collaborators of Dae Ro Choi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dae Ro Choi. Dae Ro Choi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Woo, Janghee, Dae Ro Choi, Barry E. Storer, et al.. (2019). Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. Haematologica. 105(3). 652–660. 17 indexed citations

Yoo, Changhoon, Boram Han, Hyeong Su Kim, et al.. (2018). Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. Cancer Research and Treatment. 50(4). 1324–1330. 21 indexed citations

Kim, Jung Han, Hyeong Su Kim, Bum Jun Kim, et al.. (2018). Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. Journal of Cancer. 9(22). 4279–4286. 35 indexed citations

Choi, Yunsuk, et al.. (2017). Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. The Korean Journal of Internal Medicine. 34(2). 390–400. 17 indexed citations

Han, Boram, Joo Young Jung, Hyeong Su Kim, et al.. (2016). A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer. Cancer Chemotherapy and Pharmacology. 78(5). 949–958. 1 indexed citations

Choi, Dae Ro, Sang Nam Yoon, Hyeong Su Kim, et al.. (2015). A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 75(3). 639–643. 2 indexed citations

Kim, Jung Han, Dae Young Zang, Ik‐Joo Chung, et al.. (2015). A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer. Journal of Cancer. 6(10). 1041–1048. 8 indexed citations

Jung, Joo Young, Ho Young Kim, Boram Han, et al.. (2014). The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients. BioMed Research International. 2014. 1–6. 3 indexed citations

Kim, Ho Young, Ju Kim, Dae Ro Choi, et al.. (2014). The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma. Cancer Research and Treatment. 47(3). 458–464. 4 indexed citations

10.

Han, Boram, Choong Kee Park, Jong Hyeok Kim, et al.. (2013). Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 72(4). 845–852. 12 indexed citations

11.

Kim, Hyeong Su, et al.. (2013). Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 71(6). 1591–1597. 10 indexed citations

12.

Kim, Jung Han, Hyeong Su Kim, Dae Ro Choi, et al.. (2012). Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer. Oncology Letters. 4(4). 751–754. 8 indexed citations

13.

Kwon, Jung Hye, Sung Yong Oh, Gary B. Chisholm, et al.. (2012). Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. Supportive Care in Cancer. 21(4). 1175–1183. 21 indexed citations

14.

Kwon, Jung Hye, Jung Han Kim, Jung-Ae Lee, et al.. (2010). Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 66(5). 889–897. 5 indexed citations

15.

Kim, Kyu‐pyo, Min‐Hee Ryu, Changhoon Yoo, et al.. (2010). Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemotherapy and Pharmacology. 68(2). 285–291. 16 indexed citations

16.

Kim, Hyeong Su, Gyeong‐Won Lee, Jung Han Kim, et al.. (2010). A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 70(1). 71–76. 13 indexed citations

17.

Yoon, Dok Hyun, Min‐Hee Ryu, Baek‐Yeol Ryoo, et al.. (2010). Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Investigational New Drugs. 30(2). 819–827. 24 indexed citations

18.

Kim, Jung Han, Hyeong Su Kim, Jong Soo Choi, et al.. (2008). Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer. Lung Cancer. 64(1). 121–123. 2 indexed citations

19.

Choi, Dae Ro, et al.. (2005). Long-term follow-up of alpha-interferon treatment in patients with HBeAg-positive chronic hepatitis B.. The Korean Journal of Internal Medicine. 69(2). 150–156. 1 indexed citations

20.

Jang, Myoung Kuk, Dae Ro Choi, Ja Young Lee, et al.. (2005). Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission. Journal of Infection. 51(4). 314–317. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact